medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2008, Number 4

<< Back Next >>

Acta Ortop Mex 2008; 22 (4)

Diagnosis of the peripheral hereditary neuropathies and its molecular genetics

Hernández-Zamora E, Arenas-Sordo ML

Language: Spanish
References: 97
Page: 268-277
PDF size: 187.96 Kb.


ABSTRACT

Peripheral neuropathies include a wide range of pathological disorders characterized by damage of peripheral nerves. Among them, peripheral hereditary neuropathies are a group of frequent illnesses and early evolution. They have been named hereditary motor and sensory neuropathy (HMSN) or peripheral hereditary neuropathies type Charcot-Marie-Tooth (CMT). The most frequent types are CMT1, CMT2 and CMTX. Approximately 70% of the cases correspond to subtype CMT1A, associated with tandem duplication of a 1.5 Mb DNA fragment on chromosome 17p11.2-p12 that codifies the peripheral myelin protein PMP22. So far, there five different types of CMT (1,2,3,4,X) with approximately 32 subtypes, associated with more than 30 genes. Have been reported genetic heterogeneity and expression variability of the illness makes it necessary to carry on diagnostic strategies that integrate clinical study for determining genetic clinical history, family history, complete physical exploration, muscular strength, physical deformities, reflexes and sensitivity, and molecular studies allow detection of different types of mutations and help establish a correct diagnosis and an adequate genetic counseling.


REFERENCES

  1. Salamanca-Gómez F: Avances en el estudio de las enfermedades neurodegenerativas. Gac Med Méx 2001; 137(5): 487-8.

  2. Luciano CA: Aspectos importantes en el diagnóstico y manejo de las neuropatías periféricas. Rev Neuros 1999; 29(2): 184-8.

  3. Fernández JM, Mederer S: Neuropatías y neuronopatías sensitivas. Rev Neurol 2000; 30(6): 529-31.

  4. Stógbauer F: Genética de las neuropatías hereditarias. Rev neurol 2001; 32(2): 156-64.

  5. Palau F, Cuesta A, Pedrola L: Avances en la genética molecular de las neuropatías hereditarias. Rev Neurol 2002; 35(3): 246-53.

  6. Keller MP, Chance PF: Inherited neuropathies from gene to disease. Brain Pathol 1999; 9(2): 327-4.

  7. Pearce JMS: Howard Henry Tooth (1856-1925). J Neurol 2000; 247: 3-4.

  8. Benstead TJ, Grant IA: Progress in clinical neurosciences: Charcot-Marie-Tooth disease and related inherited peripheral neuropathies. Can J Neurol Sci 2001; 28(3): 199-214.

  9. Sevilla T: Genética de la enfermedad de Charcot-Marie-Tooth tipo 1, de las neuropatías focales hereditarias y de las neuropatías hereditarias motoras distales. Rev neurol 2000; 30(1): 71-9.

  10. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, Ogawara K, Hattori N, Hirayama M, Sobue G, Kaji R: Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 2004; 127(Pt 1): 203-11.

  11. Papazian O. Alfonso I, García F: Evaluación neurofisiológica de los niños con neuropatías periféricas. Rev Neurol 2002; 35(3): 254-68.

  12. Santiago S, Espinosa ML, Pérez-Conde MC, Merino M, Ferrer T: Afectación de fibras finas en la patología del nervio periférico. Rev Neurol 1999; 28(6): 543-54.

  13. Espinosa ML, Santiago S, Guzmán, Prieto J, Ferrer T: Estudio neurofisiológico de fibras mielinizadas finas y amielínicas. Rev Neurol 1999; 28(6): 535-43.

  14. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D: Técnicas clínicas para el examen físico neurológico. I. Organización general, nervios craneales y nervios raquídeos periféricos. Rev Neurol 2004; 39(8): 757-66.

  15. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D: Técnicas clínicas para el examen físico neurológico. II. Funciones motora y refleja. Rev Neurol 2004; 39(9): 848-59.

  16. Rodríguez-García PL, Rodríguez-Pupo L, Rodríguez-García D: Técnicas clínicas para el examen físico neurológico. III. Funciones sensoriales. Rev Neurol 2004; 39(10): 966-71.

  17. Amo-Usanos C, Martín-Jiménez S, Basurte-Villamor P, Puente-Muñoz AI, Amo-Merino P, Amo-Usanos I, Franco-Carcedo C, González-Hidalgo M: Sobre el diagnóstico de las neuropatías periféricas: estudio clínico y neurofisiológico. Rev Neurol 2001; 32(2): 123-26.

  18. Kochanski A: Charcot-Marie-Tooth disorders: past, today and tomorrow. Neurol Neurochir Pol 2006; 40(4): 327-35.

  19. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, et al: DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991; 66(2): 219-32.

  20. Lupski JR: Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Pediatr Res 1999; 45(2): 159-65.

  21. Hanemann CO, Muller HW: Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy. Trends Neurosci 1998; 21(7): 282-6.

  22. Roa BB, Greenberg F, Gunaratne P, Sauer CM, Lubinsky MS, Kozma C, Meck JM, Magenis RE, Shaffer LG, Lupski JR: Duplication of the PMP22 gene in 17p partial trisomy patients with Charcot-Marie-Tooth type-1 neuropathy. Hum Genet 1996; 97(5): 642-9.

  23. Chance PF, Bird TD, Matsunami N, Lensch MW, Brothman AR, Feldman GM: Trisomy 17p associated with Charcot-Marie-Tooth neuropathy type 1A phenotype: evidence for gene dosage as a mechanism in CMT1A. Neurology 1992; 42(12): 2295-9.

  24. Suter U, Moskow JJ, Welcher AA, Snipes GJ, Kosaras B, Sidman RL, Buchberg AM, Shooter EM: Leucine-to-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse. Proc Natl Acad Sci U S A 1992; 89(10): 4382-6.

  25. Niemann S, Sereda MW, Suter U, Griffiths IR, Nave KA: Uncoupling of myelin assembly and schwann cell differentiation by transgenic overexpression of peripheral myelin protein 22. J Neurosci 2000; 20(11): 4120-8.

  26. Hanemann CO, Stoll G, D’Urso D, Fricke W, Martin JJ, Van Broeckhoven C, Mancardi GL, Bartke I, Muller HW: Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies. J Neurosci Res 1994; 37(5): 654-9.

  27. Marques W Jr, Sweeney MG, Wood NW: Thr(118)Met amino acid substitution in the peripheral myelin protein 22 does not influence the clinical phenotype of Charcot-Marie-Tooth disease type 1A due to the 17p11.2-p12 duplication. Braz J Med Biol Res 2003; 36(10): 1403-7.

  28. Suter U, Snipes GJ, Schoener-Scott R, Welcher AA, Pareek S, Lupski JR, Murphy RA, Shooter EM, Patel PI: Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters. J Biol Chem 1994; 269(41): 25795-808.

  29. Harding AE. From the syndrome of Charcot, Marie and Tooth to disorders of peripheral myelin proteins. Brain 1995; 118 (Pt 3): 809-18.

  30. D’Urso D, Schmalenbach C, Zoidl G, Prior R, Muller HW: Studies on the effects of altered PMP22 expression during myelination in vitro. J Neurosci Res 1997; 48(1): 31-42.

  31. Blair IP, Kennerson ML, Nicholson GA: Detection of Charcot-Marie-Tooth type 1A duplication by the polymerase chain reaction. Clin Chem 1995; 41(8 Pt 1): 1105-8.

  32. Suter U, Welcher AA, Ozcelik T, Snipes GJ, Kosaras B, Francke U, Billings-Gagliardi S, Sidman RL, Shooter EM: Trembler mouse carries a point mutation in a myelin gene. Nature 1992; 356(6366): 241-4.

  33. Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U: Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet 1995; 11(3): 274-80.

  34. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontes M: Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996; 5(5): 563-9.

  35. Chies R, Nobbio L, Edomi P, Schenone A, Schneider C, Brancolini C: Alterations in the Arf6-regulated plasma membrane endosomal recycling pathway in cells overexpressing the tetraspan protein Gas3/PMP22. J Cell Sci 2003; 116(Pt 6): 987-99.

  36. Atanasoski S, Scherer SS, Nave KA, Suter U: Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A. J Neurosci Res 2002; 67(4): 443-9.

  37. Sancho S, Young P, Suter U: Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A. Brain 2001; 124(Pt 11): 2177-87.

  38. Sancho S, Magyar JP, Aguzzi A, Suter U: Distal axonopathy in peripheral nerves of PMP22-mutant mice. Brain 1999; 122 (Pt 8): 1563-77.

  39. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontes M: Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 1996; 5(5): 563-9.

  40. Robertson AM, Perea J, McGuigan A, King RH, Muddle JR, Gabreels-Festen AA, Thomas PK, Huxley C: Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A. J Anat 2002; 200(4): 377-90.

  41. Suter U, Welcher AA, Snipes GJ: Progress in the molecular understanding of hereditary peripheral neuropathies reveals new insights into the biology of the peripheral nervous system. Trends Neurosci 1993; 16(2): 50-6.

  42. Reiter LT, Murakami T, Koeuth T, Gibbs RA, Lupski JR: The human COX10 gene is disrupted during homologous recombination between the 24 kb proximal and distal CMT1A-REPs. Hum Mol Genet 1997; 6(9): 1595-603.

  43. Boerkoel CF, Inoue K, Reiter LT, Warner LE, Lupski JR: Molecular mechanisms for CMT1A duplication and HNPP deletion. Ann N Y Acad Sci 1999; 883: 22-35.

  44. Badano JL, Inoue K, Katsanis N, Lupski JR: New polymorphic short tandem repeats for PCR-based Charcot-Marie-Tooth disease type 1A duplication diagnosis. Clin Chem 2001; 47(5): 838-43.

  45. Latour P, Boutrand L, Levy N, Bernard R, Boyer A, Claustrat F, Chazot G, Boucherat M, Vandenberghe A: Polymorphic short tandem repeats for diagnosis of the Charcot-Marie-Tooth 1A duplication. Clin Chem 2001; 47(5): 829-37.

  46. Inoue K, Dewar K, Katsanis N, Reiter LT, Lander ES, Devon KL, Wyman DW, Lupski JR, Birren B: The 1.4-Mb CMT1A duplication/HNPP deletion genomic region reveals unique genome architectural features and provides insights into the recent evolution of new genes. Genome Res 2001; 11(6): 1018-33.

  47. Reiter LT, Murakami T, Koeuth T, Pentao L, Muzny DM, Gibbs RA, Lupski JR: A recombination hotspot responsible for two inherited peripheral neuropathies is located near a mariner transposon-like element. Nat Genet 1996; 12(3): 288-97.

  48. Hurles ME: Gene conversion homogenizes the CMT1A paralogous repeats. BMC Genomics 2001; 2(1): 11.

  49. Yamamoto M, Keller MP, Yasuda T, Hayasaka K, Ohnishi A, Yoshikawa H, Yanagihara T, Mitsuma T, Chance PF, Sobue G: Clustering of CMT1A duplication breakpoints in a 700 bp interval of the CMT1A-REP repeat. Hum Mutat 1998; 11(2): 109-13.

  50. Bishop AJ, Schiestl RH: Homologous Recombination and Its Role in Carcinogenesis. J Biomed Biotechnol 2002; 2(2): 75-85.

  51. Stankiewicz P, Park SS, Inoue K, Lupski JR: The evolutionary chromosome translocation 4:19 in Gorilla gorilla is associated with microduplication of the chromosome fragment syntenic to sequences surrounding the human proximal CMT1A-REP. Genome Res 2001; 11(7): 1205-10.

  52. Keller MP, Seifried BA, Chance PF: Molecular evolution of the CMT1A-REP region: a human- and chimpanzee-specific repeat. Mol Biol Evol 1999; 16(8): 1019-26.

  53. Pentao L, Wise CA, Chinault AC, Patel PI, Lupski JR: Charcot-Marie-Tooth type 1A duplication appears to arise from recombination at repeat sequences flanking the 1.5 Mb monomer unit. Nat Genet 1992; 2(4): 292-300.

  54. Han LL, Keller MP, Navidi W, Chance PF, Arnheim N: Unequal exchange at the Charcot-Marie-Tooth disease type 1A recombination hot-spot is not elevated above the genome average rate. Hum Mol Genet 2000; 9(12): 1881-9.

  55. Fabrizi GM, Cavallaro T, Taioli F, Orrico D, Morbin M, Simonati A, Rizzuto NM: Uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22. Neurology 1999; 53(4): 846-51.

  56. Joo IS, Ki CS, Joo SY, Huh K, Kim JW: A novel point mutation in PMP22 gene associated with a familial case of Charcot-Marie-Tooth disease type 1A with sensorineural deafness. Neuromuscul Disord 2004; 14(5): 325-8.

  57. Abe KT, Lino AM, Hirata MT, Pavanello RC, Brotto MW, Marchiori PE, Zatz M: A novel stop codon mutation in the PMP22 gene associated with a variable phenotype. Neuromuscul Disord 2004; 14(5): 313-20.

  58. Roa BB, García CA, Pentao L, Killian JM, Trask BJ, Suter U, Snipes GJ, Ortiz-López R, Shooter EM, Patel PI, et al: Evidence for a recessive PMP22 point mutation in Charcot-Marie-Tooth disease type 1A. Nat Genet 1993; 5(2): 189-94.

  59. Roa BB, García CA, Suter U, Kulpa DA, Wise CA, Mueller J, Welcher AA, Snipes GJ, Shooter EM, Patel PI, et al: Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. Int J Neurol 1991-1992; 25-26: 97-107.

  60. Roa BB, García CA, Suter U, Kulpa DA, Wise CA, Mueller J, Welcher AA, Snipes GJ, Shooter EM, Patel PI, et al: Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med 1993; 329(2): 96-101.

  61. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B, Swanson PD, Odelberg SJ, Disteche CM, Bird TD: DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993; 72(1): 143-51.

  62. Yoshikawa H, Nishimura T, Nakatsuji Y, Fujimura H, Himoro M, Hayasaka K, Sakoda S, Yanagihara T: Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with Charcot-Marie-Tooth disease type 1A. Ann Neurol 1994; 35(4): 445-50.

  63. Kennerson ML, Nassif NT, Dawkins JL, DeKroon RM, Yang JG, Nicholson GA: The Charcot-Marie-Tooth binary repeat contains a gene transcribed from the opposite strand of a partially duplicated region of the COX10 gene. Genomics 1997; 46(1): 61-9.

  64. Bernard R, Boyer A, Negre P, Malzac P, Latour P, Vandenberghe A, Philip N, Levy N: Prenatal detection of the 17p11.2 duplication in Charcot-Marie-Tooth disease type 1A: necessity of a multidisciplinary approach for heterogeneous disorders. Eur J Hum Genet 2002; 10(5): 297-302.

  65. Bissar-Tadmouri N, Parman Y, Boutrand L, Deymeer F, Serdaroglu P, Vandenberghe A, Battaloglu E: Mutational analysis and genotype/phenotype correlation in Turkish Charcot-Marie-Tooth Type 1 and HNPP patients. Clin Genet 2000; 58(5): 396-402.

  66. Dickson KM, Bergeron JJ, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ: Association of calnexin with mutant peripheral myelin protein-22 ex vivo: a basis for «gain-of-function» ER diseases. Proc Natl Acad Sci U S A 2002; 99(15): 9852-7.

  67. Young P, Stogbauer F, Wiebusch H, Lofgren A, Timmerman V, Van Broeckhoven C, Ringelstein EB, Assmann G, Funke H: PCR-based strategy for the diagnosis of hereditary neuropathy with liability to pressure palsies and Charcot-Marie-Tooth disease type 1A. Neurology 1998; 50(3): 760-3.

  68. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, Kamholz J, Shy ME: Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 (Pt 7): 1516-27.

  69. Kovach MJ, Lin JP, Boyadjiev S, Campbell K, Mazzeo L, Herman K, Rimer LA, Frank W, Llewellyn B, Wang Jabs E, Gelber D, Kimonis VE: A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am J Hum Genet 1999; 64(6): 1580-93.

  70. Sanders CR, Ismail-Beigi F, McEnery MW: Mutations of peripheral myelin protein 22 result in defective trafficking through mechanisms which may be common to diseases involving tetraspan membrane proteins. Biochemistry 2001; 40(32): 9453-9.

  71. Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T: PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000; 14(6): 704-18.

  72. Combarros O, Calleja J, Polo JM, Berciano J: Prevalence of hereditary motor and sensory neuropathy in Cantabria. Acta Neurol Scand 1987; 75(1): 9-12.

  73. Harding AE, Thomas PK: Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980; 17(5): 329-36.

  74. Berghoff C, Berghoff M, Leal A, Morera B, Barrantes R, Reis A, Neundorfer B, Rautenstrauss B, Del Valle G, Heuss D: Clinical and electrophysiological characteristics of autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2B) that maps to chromosome 19q13.3. Neuromuscul Disord 2004; 14(5): 301-6.

  75. Tang BS, Luo W, Xia K, Xiao JF, Jiang H, Shen L, Tang JG, Zhao GH, Cai F, Pan Q, Dai HP, Yang QD, Xia JH, Evgrafov OV: A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet 2004; 114(6): 527-33.

  76. Phillips LH, Kelly TE, Schnatterly P, Parker D: Hereditary motor-sensory neuropathy (HMSN): possible X-linked dominant inheritance. Neurology 1985; 35(4): 498-502.

  77. Fain PR, Barker DF, Chance PF: Refined genetic mapping of X-linked Charcot-Marie-Tooth neuropathy. Am J Hum Genet 1994; 54(2): 229-35.

  78. Bergoffen J, Trofatter J, Pericak-Vance MA, Haines JL, Chance PF, Fischbeck KH: Linkage localization of X-linked Charcot-Marie-Tooth disease. Am J Hum Genet 1993; 52(2): 312-8.

  79. Kim HJ, Sohn KM, Shy ME, Krajewski KM, Hwang M, Park JH, Jang SY, Won HH, Choi BO, Hong SH, Kim BJ, Suh YL, Ki CS, Lee SY, Kim SH, Kim JW: Mutations in PRPS1 which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5). Am J Hum Genet 2007; 81(3): 552-8.

  80. Othmane BK, Loeb D, Hayworth-Hodgte R, Hentati F, Rao N, Roses AD, Hamida MB, Pericak-Vance MA, Vance JM: Physical and genetic mapping of the CMT4A locus and exclusion of PMP-2 as the defect in CMT4A. Genomics 1995; 28: 286-90.

  81. Balestrini MR, Cavaletti G, D’Angelo A, Tredici G: Infantile hereditary neuropathy with hypomyelination: report of two siblings with different expressivity. Neuropediatrics 1991; 22(2): 65-70.

  82. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR: Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18(4): 382-4.

  83. Gabreels-Festen A: Dejerine-Sottas syndrome grown to maturity: overview of genetic and morphological heterogeneity and follow-up of 25 patients. J Anat 2002; 200(4): 341-56.

  84. Potocki L, Chen KS, Park SS, Osterholm DE, Withers MA, Kimonis V, Summers AM, Meschino WS, Anyane-Yeboa K, Kashork CD, Shaffer LG, Lupski JR: Molecular mechanism for duplication 17p11.2- the homologous recombination reciprocal of the Smith-Magenis microdeletion. Nat Genet 2000; 24(1): 84-7.

  85. Mansfield ES, Vainer M, Harris DW, Gasparini P, Estivill X, Surrey S, Fortina P: Rapid sizing of polymorphic microsatellite markers by capillary array electrophoresis. J Chromatogr A 1997; 781(1-2): 295-305.

  86. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR: Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997; 69(3): 325-31.

  87. Choi JR, Lee WH, Sunwoo IN, Lee EK, Lee CH, Lim JB: Effectiveness of real-time quantitative PCR compare to repeat PCR for the diagnosis of Charcot-Marie-Tooth Type 1A and hereditary neuropathy with liability to pressure palsies. Yonsei Med J 2005; 46(3): 347-52.

  88. Gibbons B, Datta P, Wu Y, Chan A, Al Armour J: Microarray MAPH: accurate array-based detection of relative copy number in genomic DNA. BMC Genomics 2006; 7: 163-70.

  89. Arenas-Sordo ML, Hernández-Zamora E, Gómez-Ortega R, Valdés-Flores M, Lona-Pimentel S, Castillo-Herrera M: Molecular study of a Mexican family with PMP22 duplication and a great phenotypic variability. Cir Cir 2008; 76(5): en prensa.

  90. Hernández-Zamora E, Arenas-Sordo ML, Escobar Cedillo RE, González Huerta NC, Leyva García N, Maldonado-Rodríguez R: Strategies for clinical and molecular diagnosis of Charcot-Marie-Tooth 1A among Mexican patients. Gac Med Mex 2007; 143(5): 383-9.

  91. Hernández-Zamora E, Arenas-Sordo ML, Maldonado-Rodríguez R: Capillary electrophoresis for detection of PMP22 gene duplication. Study in Mexican patients. Electrophoresis 2008; 29(7): 1582-4.

  92. Hernández-Zamora E, Arenas-Sordo ML, Maldonado-Rodríguez R. Design of microarrays by virtual hybridization for the study of variants in the sites REP-CMT1A. Gac Med Mex 2008; 144(1): 1-6.

  93. Kochanski A: Charcot-Marie-Tooth disorders: past, today and tomorrow. Neurol Neurochir Pol 2006; 40(4): 327-35.

  94. Cassis ZN, Bild GS, Murguía CA: Enfermedad de Charcot Marie Tooth (Neuropatía Hereditaria Sensitivo Motora, NHSM). Manifestaciones clínicas y su tratamiento ortopédico en 21 pacientes. Rev Mex Ortop Traum 1997; 11(1): 19-22.

  95. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M: Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10(4): 396-401.

  96. Reilly MM, de Jonghe P, Pareyson D: 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord 2006; 16(6): 396-402.

  97. Grandis M, Shy ME: Current Therapy for Charcot-Marie-Tooth Disease. Curr Treat Options Neurol 2005; 7(1): 23-31.




2020     |     www.medigraphic.com